Vers13/1
FINAL PROGRAM
pitta
1
Vers13/1
FINAL PROGRAM
ORGANIZING COMMITTEE
CONFERENCE CENTRE
Z. BASHIR (UK)
G. BATTAGLIA (ITALY)
M. BEAR (USA)
D.V. BRUNO (ITALY)
G. COLLINGRIDGE (UK)
J. CONN (USA)
A. COPANI (ITALY)
F. FERRAGUTI (AUSTRIA)
P. FLOR (SWITZERLAND)
F. GASPARINI (SWITZERLAND)
R. GEREAU IV (USA)
K. HUBER (USA)
Grande Albergo Capotaormina
Via Nazionale, 105
98039 Taormina (Messina – Italy)
Phone: +39.0942.57.21.11
Fax: +39.0942.62.54.67
www.capotaorminahotel.com
M. KANO (JAPAN)
S. MACCARI (FRANCE)
J. MONN (USA)
R. NGOMBA (ITALY)
J.P. PIN (FRANCE)
R. NISTICO’ (FRANCE)
T. SALT (UK)
D.D. SCHOEPP (USA)
M. WATANABE (JAPAN)
M. ZHUO (CANADA)
S. ZUKIN (USA)
SCIENTIFIC SECRETARIAT
ORGANIZING SECRETARIAT
Ferdinando Nicoletti M.D.
Dept. Of Human Physiology and Pharmacology
University of Rome “La Sapienza”
Piazzale Also Moreo, 5 -00185 ROMA Italy
Phone: +39.06.49.91.29.69
Fax: +39.06.44.50307
E.mail; ferdinandonicoletti@hotmail.com
E.mail: nicoletti@neuromed.it
Centro Organizzazione Congressi
Via Miss Mabel Hill, 9
98039 Taormina (Messina – Italy)
Phone; +39.0942.242.93
Fax: +39.0942.242.51
E.mail: info@mglu.it
DATE TO REMEMBER
MEETING WEB SITE
Deadline for abstract submission
www.mglu.it
June 15, 2014
In the web site you will find all relevant information
Deadline for registration fee
on the Meeting on program as well congress
June 15, 2014
registration and hotel accommodation.
Deadline for hotel reservation
The website will be kept up-to-date in the months
June 15, 2014
months leading up to the Meeting.
Deadline for hotel cancellation with refund
June 20, 2014
Deadline for registration cancellation with refund
June 20, 2014
No refund will be made for cancellations received after June 20th, 2014
2
Vers13/1
FINAL PROGRAM
Sunday, September 28th
OPENING SYMPOSIUM P.M.
Chair: J.P. Pin (France) an D.D. Schoepp (USA)
4.30 4.55
Structure and function studies of the mGlu5 receptor in the design of novel
negative allosteric modulators
K.A. Bennett, A.S. Doré, K. Okrasa, J.C. Patel, M. Serrano-Vega, R. M. Cooke, J. C. Errey,
A. Jazayeri, , B. Tehan, G.R. Wiggin, J.A. Christopher and F.H. Marshall (UK)
4.55 5.20
Cryo-EM visualization of a metabotropic glutamate receptor
G. Skiniotis (USA)
5.20 5.45
Time-Resolved Fluorescent Sensors as powerful High Throughput Screening tools for
Metabotropic Glutamate Receptors
E. Trinquet (France)
5.45 6.10
Functional organization and dynamics of mGluR transmembrane domains
P. Rondard (France)
6.10 6.35
Optical analysis of receptor activation and signaling
M.J. Lohse (Germany)
6.35 7.00
Optical dissection of mGluR function
E. Isacoff (France)
7.00 7.25
Optical Control of metabotropic glutamate receptor with photoswitchable drugs
A. Llebaria, S. Pittolo, X. Gómez-Santacana, K. Eckelt, X. Rovira, J. Dalton, C. Goudet,
J.-P. Pin, A. Llobet, J. Giraldo and P. Gorostiza (Spain and France)
7.25 7.50
Fine tuning of sub-millisecond conformational dynamics controls mGluR agonist efficacy
J.P. Pin, L. Olofsson, S.Felekyan, E. Doumazane,P.Scholler, L.Fabre, J.M. Zwier, P. Rondard,
C.A.M. Seide and E. Margeat (France and Germany)
3
Welcome cocktail at Grande Albergo CapoTaormina
Vers13/1
FINAL PROGRAM
Monday, September 29th morning session
MOLECULAR AND FUNCTIONAL CHARACTERIZATION
Chair: J. Bockaert (France) and P. Worley (USA)
8.00 8.25
A genetic dissection of synaptic glutamate receptor function
R. Nicoll (USA)
8.25 8.50
Gating of the orphan GluD2 receptor by the mGlu1 receptor
L. Fagni (France)
8.50 9.15
A role for Pin1 prolyl isomerase in group 1 mGluR signaling
P. Worley (USA)
9.15 9.40
Regulation of Metabotropic Glutamate Receptor function by interacting proteins.
A. Francesconi (USA)
9.40 10.05
Surprising Consequences of metabotropic glutamate receptor heteromerization
P.J. Kammermaier (USA)
10.05 10.30
Coffee break
10.30 10.55
Molecular Mechanisms Regulating Group I Metabotropic Glutamate Receptors
K. Roche (USA)
10.55 11.20
Presynaptic release-regulating mGlu receptors: un update
A. Pittaluga (Italy)
11.20 11.45
mGluR1 modulates the production of exosomes in melanoma cells
S. Chen, A. L. Isola, Y. Wen and J. Goydos (USA)
11.45 12.10
4
Signal transduction of mGlu1 receptors in neurons and cancer cells
J.T. Wroblewski (USA)
Working lunch
Monday, September 29th afternoon session
FUNCTIONAL ANATOMY
Chair: F. Ferraguti (Austria)and R. Shigemoto (Austria)
3.15 3.40
The synaptic targeting of mGluR1 by its carboxyl-terminal domain is crucial for cerebellar function
A. Aiba (Japan)
3.40 4.05
Distinct mechanisms of short- and long-term motor learning in the cerebellum
R. Shigemoto (Austria)
4.05 4.30
Synapse-specific molecular imaging at the nanoscale in intact brain circuits
I . Katona (Hungary)
4.30 4.55
Role of Metabotropic Glutamate receptor 2/3 in hippocampal temporo-ammonic pathand
cross talk with the Gabaergic and Cholinergic systems
S. Gatti, T.M. Ballard, M. Lorez, M. Kessler, J. Messer, J. Wichmann, J.G.Wettstein,
B. Biemans, C. Risterucci and F. Knoflach (Switzerland)
4.55 5.15
Coffee break
Vers13/1
FINAL PROGRAM
5.15 5.40
Is there a Master Plan for the specific expression of group III mGlu receptors in distinct presynaptic
axon terminals?
F. Ferraguti (Austria)
5.40 6.05
Burst firing in the mediodorsal thalamus and related cognitive circuits is modulated by
metabotropic glutamate receptors
C.S. Copeland, S.A. Neale and T.E. Salt (UK)
Monday, September 29th afternoon session
MGLU RECEPTORS AND KYNURENINES
Chair: R. Schwarcz (USA) and V. Bruno (Italy)
6.05 6.30
Kynurenine Pathway Metabolites as Modulators of Glutamatergic Neurotransmission
R. Schwarcz, K.V. Sathyasaikumar, M. Tararina, H.-Q. Wu, D.M. Bortz and J.P. Bruno (USA)
6.30 6.55
Reduced levels of xanthurenic acid in the blood of schizophrenic patients
F. Fazio, L. Lionetto, M. Curto, F. Napolitano, G. Vignaroli, M. Capi, V. Corigliano,
A. Comparelli, L. Iacovelli, G. Mauro, V. Bruno, G. Battaglia, P. Girardi, M. Simmaco,
F. Nicoletti (Italy)
6.55 7.20
Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor,
suppresses experimental autoimmune encephalomyelitis in mice
F. Fallarino, F. Fazio , C. Zappulla, S.Notartomaso, C.Busceti, A. Bessede , P. Scarselli , C.
Vacca , M. Gargaro , M. Allegrucci , L. Lionetto , M. Simmaco, M. L. Belladonna and F.
Nicoletti (Italy and France)
Buffet Dinner in Taormina – Hotel Timeo
Performance at the Greek Theatre
Tuesday, September 30th morning session
DRUG ADDICTION
Chair: A. Markou (USA) and P. Kalivas (USA)
8.00 8.25
Neural mechanisms of reward and aversion
R. Malenka, S. Lammel, E. Steinberg, N. Wall and K. Beier (USA)
8.25 8.50
Targeting mGluR1 to reverse cocaine-induced plasticity and decrease craving
M.E. Wolf, J.A. Loweth, A.F. Scheyer and K.Y. Tseng (USA)
8.50 9.15
Synaptopathies of the mGlu signalosome
O.J. Manzoni, H.G.S. Martin, A. Bilbao, D. Neuhofer, O. Lassalle, A. Thomazeau
and R. Spanagel (France and Germany)
9.15 9.40
Development of a viral construct expressing a light-activated mGluR5 receptor
(OptoXR-mGluR5) for optogenetic applications
M. F. Olive, C. Ramakrishnan, L. Fenno and K. Deisseroth (USA)
9.40 10.05
mGlu5 receptors & extinction of drug-seeking
A. J. Lawrence (Australia)
10.05 10.25
Coffee break
5
Vers13/1
FINAL PROGRAM
10.25 10.50
Using Glial Release of Glutamate onto mGluRs to Control Relapse to Drug Use
P. W. Kalivas, M.D. Scofield and C.D. Gipson (USA)
10.50 11.15
Design, Synthesis and Characterization of Small Molecule Group II Metabotropic Glutamate
Receptor Allosteric Modulators
N. Cosford (USA)
11.15 11.40
Presynaptic mGluR2 and mGluR7 receptors critically modulate psychostimulant dependence
A. Markou, X. Li, A. Stoker, D.J. Sheffler, P.J. Conn and N.D.P. Cosford (USA)
11.40 12.05
Mechanisms Underlying the mGluR2 Autoreceptor Function and its Role in Control of
Alcohol Drinking
D.M. Lovinger, Z. Zhou, M. Heilig and D. Goldman (USA)
Working lunch
Tuesday, September 30th afternoon session
DEVELOPMENT PLASTICITY AND DISORDER OF SYNAPTIC FUNCTION
Chair: M. Kano (Japan) and M. Watanabe (Japan)
3.00 3.25
Requirement of mGluR1 for experience-dependent remodeling of mouse retinogeniculate synapses
M. Kano, M. Narushima, M. Uchigashima, M. Watanabe, A. Aiba and M. Miyata (Japan)
3.25 3.50
mGluR1 sculpts heterologous inputs to cerebellar Purkinje cells
M. Watanabe and R. Ichikawa (Japan)
3.50 4.15
mGlu1 Receptors epigenetically suppresse mGlu5 Receptors in the cerebellum
S. Notartomaso, C. Zappulla, G. Mascio, M. Motolese, M. Cannella, P.Scarselli, R. Gradini,
G. Battaglia, V. Bruno, F. Nicoletti (Italy)
4.15 4.40
Coordination between translation and degradation regulates inducibility of mGluR-LTD
P. E. Castillo, M. E. Klein and B. A. Jordan (USA)
4.40 5.05
Role of Metabotropic and Ionotropic Glutamate Receptor signaling in activity-dependent
spine shrinkage
K. Zito, W.C .Oh, I.S. Stein, L.K. Parajuli, and T.C. Hill (USA)
5.05 5.25
Coffee break
Tuesday, September 30th afternoon session
SYNAPTIC PLASTICITY AND COGNITIVE FUNTIONS
Chair: G. Collingridge (UK) and Z. Bashir (UK)
5.25 5.50
Visualization of AMPA Receptor Synaptic Plasticity In Vivo
R. L. Huganir (USA)
5.50 6.15
mGlu2 receptors: are they needed?
D. Lodge, M. Byrne, L. Ceolin, S.L. Choi, B. Conway-Campbell, M. Mercier, C. Nicolas,
E. Robinson and C. Wood (UK)
6.15 6.40
GluA2 and actin regulation of mGluR-dependent long-term depression in the hippocampus
Z. Jia (Canada)
6
Vers13/1
FINAL PROGRAM
6.40 7.05
Involvement of mGlu5 in synaptic information processing in the CA3 region in vivo:
the key to pattern completion?
D. Manahan-Vaughan and H. Hagena (Germany)
7.05 7.30
Disrupted cross-laminar cortical processing in β-amyloid pathology precedes cell death
K. G. Reymann (Germany)
7.30 7.55
mGlu1 receptor-induced LTD of NMDA receptor transmission selectively at Schaffer
collateral-CA1 synapses mediates metaplasticity
Z.I. Bashir, M. Bhouri, P. A. Farrow, A. Motee, X. Yan, G. Battaglia, L. Di Menna, B. Riozzi,
F. Nicoletti and S. M. Fitzjohn (UK and Italy)
7.55 8.20
mGluR5 and Amyloid-beta mediated aberrant synaptic plasticity and object cognition deficit
K. Cho (UK)
8.20 8.45
mGluR2 Negative Allosteric Modulators compare favorably to standard of care with respect
to pro-cognitive effects in rhesus monkey
J. M. Uslaner (USA)
Tuesday, September 30th evening session
POSTER SESSION
9.00PM
ALCANTARA ROOM
Sicilian Dinner buffet at Grande Albergo Capotaormina
Wednesday, October 1st morning session
MGLU AND DEPRESSION/ANXIETY
Chair: S. Chaki (Japan) and A. Pilc (Poland)
7.45 8.10
Potential of mGlu2/3 receptor antagonists for treatment-resistant depression:
comparison with ketamine
S. Chaki (Japan)
8.10 8.35
Efficacy and Safety of a Novel mGlu2 Receptor Positive Allosteric Modulator as an
Adjunctive Treatment to an SSRI/SNRI in the Treatment of Anxious Depression
J.M. Kent, E. Daly, M. Ceusters, I. Kezic, R. Lane, P. Lim, H. De Smedt, P. De Boer,
L. Van Nueten, and W. Drevets (USA and Belgium)
8.35 9.00
Acetyl-L-carnitine as a novel proneurogenic and antidepressant drug:
contribution of mGlu2 receptors
M. Grilli, B. Cuccurazzu, V. Bortolotto, M.M. Valente, A. Koverech and P.L. Canonico (Italy)
9.00 9.25
Targeting the epigenetic control of mGlu2 to reverse the stress-induced loss of resilience:
implications for next-generation psychiatric treatments
C. Nasca, B. Bigio, D.Zelli and B.S. McEwen (USA)
9.25 9.50
The opposing efficacy of mGlu receptor agonists and antagonist in depression vs. schizophrenia
A. Pilc, A. Pałucha-Poniewiera and J.M. Wierońska (Poland)
9.50 10.10
Coffee break
10.10 10.35
Potential utility of full and partial mGlu5 NAMs in major depression and addictive disorders
J. Rook (USA)
10.35 11.00
Discovery of the mGlu5 negative allosteric modulator basimglurant (RO4917523)
G. Jaeschke, S.Kolczewski, E. Vieira, B. Büttelmann, J. Huwyler, J.U. Peters, E. Prinssen,
A. Ricci, D. Rueher, M. Schneider, P. Spurr, D. Tännler, J. Wichmann, J.G. Wettstein,
R. Porter, W. Spooren, L. Lindemann (Switzerland)
7
Vers13/1
FINAL PROGRAM
Wednesday, October 1st morning session
PAIN
Chair: M. Zhuo (Canada)and V.Neugebauer (USA)
11.00 11.25
Pain-related mGluR modulation of medial prefrontal cortex-amygdala interactions
V. Neugebauer, G. Ji and T. Kiritoshi (USA)
11.25 11.50
Metabotropic glutamate receptor (mGluR) dependent synaptic plasticity in pain-related
cortex and their roles in chronic pain
M. Zhuo (Canada)
11.50 12.15
Broad spectrum efficacy with LY2969822, a metabotropic glutamate2/3 agonist prodrug of
LY2934747, in rodent pre-clinical pain models.
M.P. Johnson, M.A. Muhlhauser, E. Nisenbaum, R.M.A. Simmons,B. Forster, K.L. Knopp,
L. Yang, D. Morrow, D.L. Li, J.D. Kennedy, and J.A. Monn (USA)
12.15 12.40
Fenobam: a clinical tool compound for assessment of the role of mGlu5 in human pain processing
L.F. Cavallone, M.C. Montana, K. Frey, M. Wages, K. Regina and R.W. Gereau IV (USA)
12.40 13.05
N-acylethanolamines modulate glutamate transmission in the prelimbic cortex of neuropathic mouse
S. Maione, L. Luongo, R. Romano, F. Guida, S. Boccella, F. Napolitano, V. de Novellis
and A. Usiello (Italy)
Working lunch
Wednesday, October 1st afternoon session
PHARMACOLOGY AND DRUG DEVELOPMENT
Chair : J. Monn (USA) and F. Acher (France)
3.00 3.20
LY2491503, A Novel mGluR1 Antagonist for Persistent Pain: From Clone to Clinic
E.S.Nisenbaum, S. Iyengar, K.L. Knopp, R.M. Simmons, D. Li, M.J. Fisher, S. Kuklish, V.N. Barth,
M.G. Chambers, B.A. Heinz, S.A. Monk, P. Zanotti-Fregonara, J-S Liow, R. Xu, V.W. Pike, R.B. Innis
and L.A. Arendt-Nielsen (Denmark and USA)
3.20 3.40
LY2934747: In Vitro and In Vivo Characterization of a Novel mGlu2/3 Receptor Agonist
D. McKinzie, B. Heinz, X. Wang, D. Schober, C. Felder, H. Sanger, R. Vivier, E. Siuda,
E. Nisenbaum, L. Thompson, B. Johnson, K. Knitowski, D. Shaw, L. Rorick-Kehn, J. Katner,
K. Perry, M. Johnson, C. Beadle, S. Atwell, F. Lu, D. Clawson, M. Bures, S. Swanson and
J. Monn (USA and UK)
3.40 4.00
Discovery and early clinical evaluation of a novel mGlu2 Receptor Positive Allosteric Modulator
P. De Boer, H. Lavreysen, I. Kezic, M. Ceusters, H.De Smedt, L. Van Nueten, W. Drevets and
J.M. Kent (Belgium and USA)
4.00 4.20
Discovery of LY3020371, a potent and selective mGlu2/3 receptor antagonist, for the
treatment of depression
J.M. Witkin and J.A. Monn (USA)
4.20 4.40
Discovery of novel mGlu3-selective allosteric modulators provides new
insights into mGlu3 function
C. Wenthur (USA)
4.40 5.00
Coffee break
8
Vers13/1
FINAL PROGRAM
5.00 5.20
New orthosteric group-III mGluR ligands
F.C. Acher, B. Commare, I. Brabet, D. Rigault, Bertrand H.-O., C. Goudet and J.-P. Pin (France)
5.20 5.40
Supra-Physiological Pharmacology by mGlu4 Receptor Positive Allosteric Modulators
X. Huang, M. D. Collins, N. J. Boyle, H. Zhang, E. Dale, M. Jørgensen, C. Bundgaard, L. K. Isaac,
M. H. Schmidt, H. Zhong, F. C. Acher, R. M.Brodbeck and D.Doller (USA, Denmark and France)
5.40 6.00
The Discovery and Preclinical Characterization of the Novel mGluR5 Negative Allosteric
Modulator PF470: Implications for Mechanism-based Toxicity?
C. L. Shaffer (USA)
6.00 6.20
Progress Towards Novel Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric
Modulators for CNS disorders
S. Célanire (Switzerland)
Wednesday, October 1st afternoon session
REGULATION OF THALAMO-CORTICAL NETWORK
Chair: J. Huguenard (USA) and R. Ngomba (Italy)
6.20 6.45
mGlu2 Receptors and sensory processing in the thalamus; a tale of astrocytes and neurones
T.E. Salt, C.S Copeland, H.R. Parri, T.M. Wall, S.A. Neale and E. Nisenbaum (UK and USA)
6.45 7.10
Role of thalamic mGluRs in EEG rhythms of wake and sleep
V. Crunelli (UK)
7.10 7.35
Modulation of Extrasynapitic GABAA Receptors by mGLU Receptors
G. Di Giovanni, V. Crunelli and A. C. Errington (Malta and UK)
7.35 8.00
Group III metabootropic receptors modulate synaptic plasticity in the corticothalamic circuit
J. Huguenard and C. Kyuyoung (USA)
8.00 8.25
Is there a future for Group I PAMs in epilepsy?
G. Van Luijtelaar and R. Ngomba (The Netherlands and Italy))
9
Beach party at Grande Albergo Capotaormina
Vers13/1
FINAL PROGRAM
Thursday, October 2nd morning session
SCHIZOPHRENIA
Chair: J.Conn (USA) and F. Matrisciano (USA)
7.45 8.10
Targeting glutamate neurotransmission for prevention of psychosis
B. Moghaddam (USA)
8.10 8.35
Allosteric modulator effects and physiological roles of mGlu receptor heterodimers in
identified brain circuits
P. J. Conn, A. Ghoshal, X. Xiang, J.M. Rook, C.W. Lindsley, S. Yen, C.K. Jones, and
C.M. Niswender (USA)
8.35 9.00
DNA methylation and hydroxymethylation in psychiatric disease.
D.R. Grayson and A. Guidotti (USA)
9.00 9.25
Structural insights into the crosstalk mechanism between 5-HT2A and mGlu2
receptors in schizophrenia
J. González Maeso (USA)
9.25 9.50
Functional brain imaging of experimental Group II metabotropic glutamate receptor
(mGluR) agonists LY2979165 and LY2140023 in healthy human subjects
A. J. Schwarz, A. Schmechtig, J. McColm, K. Jackson, C. Brittain, C. Gonzales,
S. Suriyapperuma, J. Foster, S. Tauscher-Wisniewski, B. Kinon and M.A. Mehta (USA)
9.50 10.10
Coffee break
10.10 10.35
The development of pomaglumetad methionil as a glutamate-based pharmacotherapy for
schizophrenia: lessons learned
V. L. Stauffer (USA)
10.35 11.00
Glutamate Receptors genes and schizophrenia
M. Gennarelli and E. Sacchetti (Italy)
Thursday, October 2nd morning session
NEURODEVELOPMENT/AUTISM
Chair: W. Spooren (Switzerland) and B.K. Kaang (Korea)
11.00 11.25
EU-AIMS: mGlu1 from mouse to patient
D. Murphy (UK)
11.25 11.50
mGluR5 as a Fragile X Treatment Target
M.R. Tranfaglia (USA)
11.50 12.15
mGluR4 and psychiatric disorders
B. Biemans and G. Jaeschke (Switzerland)
12.15 12.40
Glutamate receptors and autism
B.K. Kaang (Korea)
Working lunch
10
Vers13/1
FINAL PROGRAM
Thursday, October 2nd afternoon session
AUTISM
Chair: K. Huber (USA) and M.V. Catania (Italy)
3.00 3.25
Targeting MAP-kinase interacting kinases restores protein synthesis homeostasis and
improves behavioral deficits in neuroligin-3 mouse model of autism
S. Baudouin, L. Burkle and P. Scheiffele (Switzerland and UK)
3.25 3.50
Regulation of mGluR5-Homer scaffolds in Fragile X Syndrome mice
K.M. Huber, W. Guo, K.A. Collins, G. Molinaro and P. F. Worley (USA)
3.50 4.15
Dysfunctions of metabotropic glutamate receptor subtype 5 (mGlu5) receptors in a mouse
model of Fragile X syndrome
M.V. Catania, M. Spatuzza, E. Aloisi, S. D’Antoni, J.P. Dupuis, L Costa, C. M. Bonaccorso,
G. Molinaro, G. Battaglia, S. Musumeci, L. Davidovic, B. Bardoni, L. Ciranna, F. Nicoletti,
L. Groc and A. Frick (Italy and France)
4.15 4.40
Activity-dependent Arc expression: mechanism, function and application
H. Bito (Japan)
4.40 4.55
Coffee break
4.55 5.20
Mutations of the SHANK genes and alterations of mGlu5 signaling
C. Sala, C. Verpelli, C. Vicidomini and D.I. Orellana (Italy)
5.20 5.45
Aberrant cofilin signaling in a mouse model of Fragile X syndrome
S. Zukin (USA)
5.45 6.10
Synaptic and Circuit Mechanisms for Striatal mGluR5 Signaling in Compulsive Behaviors
N. Calakos (USA)
6.10 6.35
Metabotropic glutamate receptor 7: a novel target for the treatment of Rett Syndrome
C.M. Niswender, R. Klar, R.G. Gogliotti, R. Zamorano, A.G. Walker, Z. Xiang and P.J. Conn (USA)
6.35 7.00
Structural Plasticity of Dendritic Spines During Long-Term Depression
M. Bosch and M. Bear (USA)
7.00 7.25
Facilitating glutamate mGluR4 receptor signaling relieves autistic-like deficits in mice
J. Le Merrer, J.A.J. Becker and B.L. Kieffer (France and Canada)
Dinner at Taormina’s Garden
Mediterranean buffet with music and cabaret
11
Vers13/1
FINAL PROGRAM
Friday, October 3rd morning session
EMERGING ROLES FOR MGLU7 AND MGLU8 RECEPTORS AS DRUG TARGETS
IN NEURAL AND SOMATIC DISORDERS
Chair: P. Flor (Germany) and J.F. Cryan (Ireland)
7.45 8.10
Therapeutic Potential of Orthosteric and Allosteric mGlu7 Receptor Drugs
P. J. Flor, C.E. Gee, D. Peterlik, N. Uschold-Schmidt, J. F. Cryan, R. Bouhelal,
M. Fendt, F. Gasparini, I. Vranesic, R. Glatthar and H. van der Putten (Germany and Ireland)
8.10 8.35
mGlu7: A therapeutic target for stress-related disorders of brain and gut
J.F. Cryan (Ireland)
8.35 9.00
mGlu7 Receptor Modulation Relieves Behavioral and Physiological Consequences Induced
by Chronic Psychosocial Stress
N. Uschold-Schmidt D. Peterlik, A. Bludau, T. Killian, D. Grabski, S. O. Reber and P. J.Flor
(Germany)
9.00 9.25
The last mGlu: Is mGlu8 a therapeutic target?
R.M. Duvoisin and J. Raber (USA)
9.25 9.50
Role of mGlu7 and mGlu8 receptors in event learning
M. Fendt (Germany)
9.50 10.10
Coffee break
Friday, October 3rd morning session
EXITOTOXICITY , BRAIN ISCHEMIA AND PARKINSON’S DISEASE
Chair: G. Battaglia (Italy)and A. Copani (Italy)
10.10 10.35
Group I metabotropic glutamate receptors mediate inflammation-induced sensitization
to excitotoxic neurodegeneration
P. Gressens (France)
10.35 11.00
mGluRs in stroke
T. Wieloch (Sweden)
11.00 11.25
Role of ionotropic and metabotropic glutamate receptors in models of ischemic tolerance
D.E. Pellegrini-Giampietro, E. Gerace, E. Zianni, F. Gardoni, T. Scartabelli, E. Landucci,
F. Moroni, G. Mannaioni and M. Di Luca (Italy)
12
Vers13/1
FINAL PROGRAM
11.25 11.50
MGluR5 Antagonists and neuroprotection in Parkinson’s disease: An effect that extends
beyond dopaminergic cell groups
Y. Smith (USA)
11.50 12.15
Targeting metabotropic glutamate receptors (mGluRs) in Parkinson’s disease
M. Amalric (France)
12.15 12.40
Preclinical and clinical evaluation of dipraglurant, a novel negative allosteric modulator
(NAM) of the mGlu5 receptor for the treatment of dystonia and levodopa induced
dyskinesia
S. Poli (Switzerland)
12.40 1.05pm
mGlu5 receptors in Parkinson’s disease and MPTP-lesioned monkeys: behavior and brain
molecular correlates
T. Di Paolo, N. Morin, B. Ouattara, L. Grégoire , M. Morissette, P. Samadi, F. Gasparini,
A. Rajput , A. H. Rajput and B. Gomez-Mancilla (Canada and Switzerland)
1.05-1.30pm
Antagonism of mGluR5 to treat L-DOPA-induced dyskinesia: when and how would this
treatment work?
M.A. Cenci (Sweden)
1.05 1.30pm
mGluR3 PAM as novel neuroprotective therapeutic strategy for Parkinson’s Disease
S. Schann (France)
Working lunch
13
Vers13/1
FINAL PROGRAM
SUMMARY SCHEDULE
Symposium 1 (pag.3)
Opening Symposium
Sun, 2014-09-28
04.30pm-7.50pm
Symposium 2(pag.4)
Molecular and functional characterization
Mon, 2014-09-29
08.00am-12.10am
Symposium 3 (pag.4-5)
Functional anatomy
Mon, 2014-09-29
03.15pm-06.05pm
Symposium 4 (pag.5)
mGlu recepotrs and kynurenines
Mon, 2014-09-29
06.05pm-07.20pm
Symposium5 (pag.5-6)
Drug addiction
Tue, 2014-09-30
08.00.am -12.05am
Symposium 6 (pag.6)
Development plasticity and disorder of synaptic function
Tue, 2014-09-30
03.00pm-05.05pm
Symposium 7
(pag.6-7)
Synaptic plasticity and cognitive functions
Tue, 2014-09-30
05.25pm-08.45pm
Poster session (pag.7)- Alcantara room
Tue, 2014-09-30
09.00pm
Symposium 8(pag.7-8)
mGlu and depression/anxiety
Wed, 2014-10-01
07.45am-11.00am
Symposium 9 (pag.8)
Pain
Wed, 2014-10-01
11.00am-1.05pm
Wed, 2014-10-01
03.00pm-06.20pm
Symposium 11 (pag.9)
Regulation of thalamo-cortical network
Wed, 2014-10-01
06.20pm-08.25pm
Symposium 12 (pag.9)
Schizophrenia
Thu, 2014-10-02
07.45am-11.00am
Thu, 2014-10-02
11.00am-12.40am
Symposium 14 (pag.11)
Autism
Thu, 2014-10-02
03.00pm-07.25pm
Symposium 15 (pag.11)
Emerging roles for mGlu7 and mGlu8
receptors as drug targets in neural and somatic disorders
Fri, 2014-10-03
07.45am-09.50am
Symposium 16 (pag.11-12)
Exitotoxicity, brain ischemia and parkinson’s disease
Fri, 2014-10-03
10.10am-01.30pm
Symposium 10 (pag.8-9)
Pharmacology and drug development
Symposium 13 (pag.10)
Neurodevelpment/Autism
14